Pagoclone doesn't seem to be working out, but with trospium, Indevus may have a one more shot at comeback.
FORBES: A Biotech Phoenix Could Be Rising
2.
In June, Pfizer (nyse: PFE - news - people ) ended its collaboration with Indevus over an anti-anxiety drug called pagoclone.
FORBES: Magazine Article
3.
It began licensing compounds like pagoclone and trospium, which is licensed from Europe's Madaus AG , in the hopes that one of them would make it through the FDA's goalposts.